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Abstract  31 
While many studies evaluate predictors for ventricular arrhythmias in Arrhythmogenic Right 32 
Ventricular Cardiomyopathy (ARVC), a systematic review consolidating this evidence is currently 33 
lacking. Therefore, we searched MEDLINE and Embase for studies analyzing predictors for 34 
ventricular arrhythmias (sustained ventricular tachycardia/fibrillation (VT/VF), appropriate implantable 35 
cardioverter-defibrillator therapy, or sudden cardiac death) in definite ARVC patients, borderline 36 
ARVC patients, and ARVC-associated mutation carriers. In case of multiple publications on the same 37 
cohort, the study with the largest population was included. This yielded 45 studies with a median 38 
cohort size of 70 (IQR 60) patients and 5.0 (IQR 3.5) years follow-up. The arrhythmic outcome was 39 
observed in 10.6%/year in definite ARVC patients, 10.0%/year in borderline ARVC patients, and 40 
3.7%/year in mutation carriers. Predictors for ventricular arrhythmias were population-dependent: 41 
consistently predictive risk factors in definite ARVC patients were male sex, syncope, T-wave 42 
inversion >V3, right ventricular (RV) dysfunction, and prior (non)sustained VT/VF; in borderline ARVC 43 
patients, two additional predictors (inducibility at electrophysiology study and strenuous exercise) 44 
were identified; and in mutation carriers, all aforementioned predictors as well as ventricular ectopy, 45 
multiple ARVC-related pathogenic mutations, left ventricular dysfunction, and palpitations/pre-syncope 46 
determined arrhythmic risk. Most evidence originated from small observational cohort studies, with a 47 
moderate quality of evidence. In conclusion, the average risk of ventricular arrhythmia ranged from 48 
3.7% to 10.6%/year depending on the ARVC population. Male sex, syncope, T-wave inversion >V3, 49 
RV dysfunction, and prior (non)sustained VT/VF consistently predict ventricular arrhythmias in all 50 





Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an inherited cardiomyopathy 54 
with a high risk of ventricular arrhythmias, most notably in young individuals and athletes.1 Identifying 55 
individuals at highest risk of arrhythmias is crucial to prevent sudden cardiac death (SCD) using an 56 
implantable cardioverter-defibrillator (ICD). Conversely, recognizing subjects at low arrhythmic risk is 57 
important since ICD placement bears a considerable risk of complications and inappropriate 58 
interventions.2,3 Since the clinical expression of ARVC is variable, reliable risk prediction is difficult, 59 
which presents a challenge to physicians and patients alike. 60 
Over the years, many studies have described risk factors for ventricular arrhythmias in ARVC, 61 
including a consensus statement on ARVC treatment.4 Despite the wealth of data in the literature, 62 
most studies were non-randomized, included relatively small patient numbers, and did not account for 63 
differences in patient subgroups, leading to high variation in the reported associations. Indeed, while 64 
previous sustained ventricular arrhythmias and ventricular dysfunction are generally recognized as 65 
important predictors of arrhythmic events, the prognostic value of other risk factors remains unclear. 66 
To the best of our knowledge, a systematic review and meta-analysis summarizing the available 67 
evidence is currently lacking.  68 
 In light of these shortcomings, we systematically reviewed observational studies that 69 
assessed predictors for ventricular arrhythmias in ARVC. We evaluated the quality of evidence, 70 
quantified them using pooled analyses when appropriate, and performed sub-analyses on patient 71 
subgroups to obtain subgroup-specific risk estimates. The results of these analyses may aid clinical 72 
decision-making, counseling, and expectation management in this high-risk population. 73 
 74 
Methods 75 
This study was performed in accordance with the guidelines from the Preferred Reporting 76 
Items for Systematic Reviews and Meta-Analyses (PRISMA)5 and Meta-analysis of Observational 77 
Studies in Epidemiology (MOOSE)6. We performed a systematic search of MEDLINE and Embase in 78 
January 2017 for clinical studies on risk factors for ventricular arrhythmias in patients with ARVC. A 79 
detailed description of our search strategy, selection and data extraction can be found in the 80 




Study Eligibility and Definitions 83 
Any original study involving an ARVC population that investigated an association between ≥1 84 
risk factor(s) and a predefined arrhythmic outcome was considered eligible for inclusion in this review. 85 
The study population of interest included patients fulfilling diagnostic Task Force Criteria 86 
(TFC) for ARVC. Of note, these criteria were first described in 1994 and revised in 20107. Since 87 
restricting the patient population to either one of these criteria would inevitably lead to selection bias, 88 
both were considered eligible for inclusion. The included studies were classified in three categories 89 
(i.e. patient domains) based on their inclusion criteria: (1) “definite ARVC” refers to cohorts in which all 90 
patients fulfilled diagnostic TFC, (2) “borderline ARVC” refers to cohorts in which patients had at least 91 
a borderline ARVC diagnosis (TFC score ≥3, thus including definite ARVC patients), and (3) “mutation 92 
carriers” refers to cohorts of ARVC-associated mutation carriers regardless of phenotypic expression, 93 
thereby including both asymptomatic mutation-carrying relatives and a (small) proportion of definite 94 
ARVC patients. Since all three subgroups include definite ARVC patients, all were considered 95 
relevant for the purpose of our analyses. However, the patient domains were separately analyzed in 96 
this manuscript, since these differences in inclusion criteria is likely to affect the reported results.  97 
The outcome of interest was potentially lethal ventricular arrhythmias. All studies that included 98 
spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF), sudden cardiac arrest, SCD, 99 
or appropriate ICD intervention for a ventricular arrhythmia were considered eligible for inclusion in 100 
this study. Non-sustained VT was excluded as an outcome in our analyses. Since almost all studies 101 
exclusively reported risk estimates for a combined arrhythmic outcome, we were obliged to consider 102 
all arrhythmic outcomes as equal, although we report outcome-specific risk estimates if available. 103 
Studies that included non-arrhythmic outcomes, such as heart failure, heart transplantation or overall 104 
mortality, were excluded unless subgroup analysis for arrhythmic outcome was provided or could be 105 
reconstructed. 106 
 107 
Quality Assessment 108 
To assess the individual study quality and risk of bias, we used the Quality In Prognostic 109 
Studies (QUIPS) tool developed by the Cochrane Collaboration.8 Details can be found in the 110 
Supplementary Methods. Study quality was assessed independently by two investigators (LPB and 111 




Statistical Analysis 114 
Our analyses were divided in two components: (1) we presented a description of all studies 115 
that provided OR, risk ratios (RR), Kaplan Meier (KM) or Receiver Operator Characteristic (ROC), for 116 
every risk factor separately; (2) we pooled all studies that reported HRs in a meta-analysis, provided 117 
that the variable definitions were uniform. Only studies reporting HRs were considered for meta-118 
analysis, as ORs can only reliably be pooled when follow-up time is equal. Furthermore, meta-119 
analyses were only performed on crude (i.e. unadjusted) HRs within the same patient domain; studies 120 
selecting participants based on genotype were not pooled due to the expected high variation in 121 
phenotypic expression. All meta-analyses were conducted in Review Manager (RevMan 5.3, 122 
Copenhagen: The Cochrane Collaboration, 2014). Statistical heterogeneity between studies was 123 
assessed using the Chi-square homogeneity test, expressed by the I2 index, where I2 values indicated 124 
low(<25%), moderate(25-75%) and high(>75%) degree of heterogeneity. Study-specific crude HRs 125 
were combined using inverse variance-weighted averages of a random effects model. Sensitivity 126 
analyses were performed to assess the contribution of selection differences based on (1) TFC version 127 
and (2) primary prevention populations. 128 
 129 
Results 130 
Search Results 131 
Our search results and selection process is shown in Figure 1. Our literature search yielded 132 
712 unique records, which were carefully screened based on title and abstract. Records (n=617) that 133 
did not report on prognostic factors for arrhythmic outcomes in the appropriate population were 134 
excluded. The remaining 95 candidate publications received a thorough full-text assessment, resulting 135 
in a total of 45 studies that met the inclusion criteria, see Supplementary Reference for a full reference 136 
list of the included studies. An overview of the excluded studies with reasons for exclusion can be 137 
found in Supplementary Table 1. Potential cohort overlap was excluded at the level of the individual 138 
risk factors by maintaining only the study with the largest population as disclosed in Figure 2. 139 
 140 
Study Characteristics 141 
The 45 included studies were published between 1999 and 2017 and had a median cohort 142 
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size of 70 patients (IQR 60; range 24-541), among whom a median of 31 patients (IQR 30; range 5-143 
301) experienced arrhythmic events during a median follow-up of 5.0 years (IQR 3.5; range 3.2-7.6). 144 
The study population included definite ARVC patients in 28 studies, definite or borderline ARVC 145 
patients in 9 studies (median 76% fulfilling definite diagnosis [IQR 12; range 68-87%]), and ARVC-146 
associated mutation carriers independent of phenotypic expression in the remaining 8 studies 147 
(median 60% fulfilling definite diagnosis [IQR 4; range 34-71%]). ARVC diagnosis was based on the 148 
original 1994 TFC in 15 (33.3%) studies and the modified 2010 TFC in 30 (66.7%) studies. While 149 
most studies did not differentiate between primary or secondary prevention, ten studies excluded 150 
patients who experienced a sustained arrhythmic event prior to inclusion, and three studies included 151 
only secondary prevention patients. Figure 2 summarizes the study characteristics. 152 
 153 
Quality Assessment 154 
Using the QUIPS tool8, the risk of bias was evaluated for six pre-defined areas important in 155 
observational prognostic research; (1) study participation, (2) study attrition, (3) prognostic factor 156 
measurement, (4) outcome measurement, (5) study confounding, and (6) statistical analysis and 157 
reporting. As shown in Figure 3, the highest potential for bias was introduced by limited or absent 158 
adjustment for confounders using multivariable analysis (“study confounding”) and the use of 159 
statistical models not correcting for individual and group differences in follow-up time (“statistical 160 
analysis and reporting”). Additionally, bias due to selective loss to follow-up (“study attrition”) could not 161 
be ruled out for most studies as loss to follow-up was rarely addressed. Only studies that reported 162 
HRs were used in the meta-analysis, this subgroup of studies had a lower risk of bias given their use 163 
of the recommended statistical methods. 164 
 165 
Arrhythmic Outcome 166 
The proportion of patients in which the primary arrhythmic outcome was observed during 167 
follow-up ranged widely among studies; from 1.0%/year in a cohort of predominantly asymptomatic 168 
ARVC-associated mutation carriers, to 30.1%/year in a cohort of severely affected definite ARVC 169 
patients. The average proportion of arrhythmic events in studies with definite ARVC patients was 170 
10.6%/year (range 3.0-30.1%), in studies with borderline ARVC patients 10.0%/year (range 6.3-171 




Risk Factors for Ventricular Arrhythmia 174 
The main risk factor associations are reported by category below; all extracted results are 175 
presented in Supplementary Tables 2A-I. The pooled HRs from all meta-analyses are summarized in 176 
Figure 4; the corresponding forest plots can be found in Supplementary Figure 1.  177 
 178 
Demographics 179 
Age · was investigated as a predictor of arrhythmic events by 23 studies. The vast majority 180 
(n=21/23) of these studies reported non-significant results. Only two studies, both with definite ARVC 181 
patients, reported a higher arrhythmic risk in younger patients: below 40 years (HR 2.90, 95%CI 1.51-182 
5.58), or per year increase in age (OR 0.95, 95%CI 0.89-0.99)(Supplementary Table 2A). Meta-183 
analysis of five studies using age as a continuous variable and three studies that used a cut-off value 184 
of 35 years did not yield significant results among definite and borderline ARVC subjects (Figure 4). 185 
Male sex · was directed towards an increased risk of ventricular arrhythmias in 22 of 28 186 
studies, although statistical significance was only reached in 6/16 studies with definite and 1/6 studies 187 
with borderline ARVC patients. In contrast, significant results were obtained in all six studies with 188 
mutation carriers (Supplementary Table 2A). Meta-analysis of seven studies with definite ARVC 189 
patients confirmed a higher risk in males, pooled HR 1.83 (95%CI 1.41-2.37). The pooled result from 190 
four studies with borderline patients was similar in direction, but did not reach statistical significance, 191 
pooled HR 1.42 (95%CI 0.91-2.23)(Figure 4). 192 
Other · demographic and comorbidity risk factors were reported with no statistically significant 193 
results (Supplementary Table 2A). 194 
 195 
Symptoms 196 
Symptoms · including palpitations, chest pain, pre-syncope, and syncope were studied as 197 
predictors of arrhythmic events in 23 studies. Symptomatic participants (i.e. having any one of the 198 
abovementioned symptoms) were compared to asymptomatic participants in three studies (one with 199 
definite ARVC patients and two with mutation carriers), all reporting a significantly higher risk in the 200 
symptomatic group (Supplementary Table 2B).  201 
Unexplained syncope · was investigated as risk factor for arrhythmic events in 19 studies. 202 
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While most (n=15/19) studies were uniform in direction towards increased arrhythmic risk, statistical 203 
significance was only reached in 6/11 studies with definite ARVC patients, 1/5 studies with borderline 204 
ARVC patients, and 1/3 studies with mutation carriers (Supplementary Table 2B). Meta-analysis was 205 
feasible for five studies with definite ARVC patients and two studies with borderline ARVC patients: 206 
pooled HR 3.67 (95%CI 2.75-4.90) and pooled HR 2.04 (95%CI 0.39-10.74), respectively (Figure 4). 207 
Other · symptoms were also analyzed, for which results can be found in Supplementary Table 208 
2B. 209 
 210 
Physical Exercise 211 
Physical exercise · has frequently been associated with ARVC, although it was analyzed as a 212 
risk factor for arrhythmic events by only three studies that used non-uniform definitions 213 
(Supplementary Table 2C). Regardless, exercise was significantly associated with arrhythmic risk in 214 
all three studies. One study with definite ARVC patients reported a HR of 2.90 (95%CI 1.14-7.38) 215 
comparing patients participating in strenuous exercise to inactive patients. Similar results were found 216 
in borderline ARVC patients, comparing competitive to recreational athletes (HR 1.99 [95%CI 1.21-217 
3.28]). Likewise, a dose-related effect was found in mutation carriers who were endurance athletes, in 218 
whom reducing the level of exercise after presentation was protective of ventricular arrhythmias (OR 219 
0.05 [95%CI 0.003-0.67]). Meta-analysis was not performed given the heterogeneity in patient domain 220 
and utilized statistics. 221 
 222 
Family History and Genotype 223 
Proband status · was analyzed as a risk factor by three studies, comparing the arrhythmic risk 224 
of the proband (i.e. first patient diagnosed with ARVC in a family) to family members. Although 225 
proband status was found to be associated with arrhythmic events in two of three studies in 226 
univariable analysis, this effect was lost after correcting for confounders (Supplementary Table 2D). 227 
Meta-analysis of three studies with definite ARVC patients yielded a non-significant result (pooled HR 228 
2.01 [95%CI 0.39-10.74]) with large heterogeneity (I2 82.4%, p 0.017)(Figure 4). 229 
Family history · positive for premature SCD (defined as <35 years as per diagnostic TFC) was 230 
investigated as a risk factor by ten studies, most (n=9/10) of which reported non-significant results 231 
(Supplementary Table 2D). This non-significant predictive effect was confirmed in meta-analysis in 232 
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definite ARVC patients (four studies, pooled HR 1.25 [95%CI 0.86-1.8]), and borderline ARVC 233 
patients (two studies, pooled HR 1.21 [95%CI 0.39-3.80]; Figure 4). 234 
Pathogenic mutation · carriers were compared to patients without mutations by four studies. 235 
While two studies found that arrhythmias occurred at a younger age in mutation carriers, three studies 236 
compared the risk of arrhythmias from the age of presentation and reported no significant difference 237 
(Supplementary Table 2D). Meta-analysis was not performed given the heterogeneity in patient 238 
domain and utilized statistics. 239 
Multiple mutations · including compound heterogeneity and mutations in ≥1 ARVC-associated 240 
gene was investigated as a risk factor by two studies of which one reported an increased arrhythmic 241 
risk (HR 3.01 [95%CI 1.42-6.37]), and the other found a significantly younger age at time of the 242 
arrhythmic event (Supplementary Table 2D). 243 
Other · reported risk factors defined by family history and genotype, including combinations of 244 
the two, can be found in Supplementary Table 2D.  245 
 246 
Electrocardiography 247 
T-wave inversion (TWI)· on a standard 12-lead ECG was investigated as a risk factor by 21 248 
studies. Fulfilling a minor repolarization criterion (i.e. TWI in leads V1-2; V4, V5, V6; or V1-4 in 249 
presence of complete right bundle branch block) was not associated with arrhythmic events in most 250 
(n=3/4) studies regardless of patient domain. Fulfilling a major repolarization criterion (i.e. TWI in V1-251 
3) had no predictive value in definite ARVC patients (five studies), while the results in borderline 252 
patients were conflicting (i.e. both significantly predictive and protective effects were reported; two 253 
studies), and analyses in mutation carriers reported a significant association with arrhythmic events 254 
(two studies). The remaining eight studies showed that a greater extent of TWI (i.e. >V3 or in inferior 255 
leads) is a significant risk factor in all patient domains (Supplementary Table 2E). Meta-analysis was 256 
only feasible for four studies reporting TWI V1-3 in definite ARVC patients; pooled HR 1.18 (95%CI 257 
0.86-1.62)(Figure 4). 258 
Epsilon waves · are defined as reproducible low-amplitude signals between the end of the 259 
QRS and the T-wave, separated from the QRS complex. Epsilon waves were investigated as a risk 260 
factor by ten studies, of which 4/10 reported a significantly predictive effect. Meta-analysis was 261 
feasible for two studies with definite ARVC patients (pooled HR 1.17 [95%CI 0.34-4.01]) and two 262 
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studies with borderline ARVC patients (pooled HR 1.58 [95%CI 0.90-2.77]), both directed towards 263 
increased arrhythmic risk, although statistical significance was not reached (Figure 4). 264 
Prolonged terminal activation duration (TAD) · is measured from the S-nadir to the end of all 265 
depolarization deflections, and defined as prolonged if ≥55 milliseconds in any of the leads V1-3. 266 
Prolonged TAD was investigated as a risk factor by four studies with non-consistent results: an 267 
association with ventricular arrhythmias was noted in 1/1 study with definite ARVC patients, 0/1 study 268 
with borderline ARVC patients, and 1/2 studies with mutation carriers (Supplementary Table 2E). 269 
Meta-analysis was not feasible due to heterogeneity in patient domain and utilized statistics. 270 
Late potentials · are defined as the presence of filtered QRS duration ≥114ms, low-amplitude 271 
signal duration ≥38ms, or root-mean square of terminal QRS ≤20uV measured by signal-averaged 272 
ECG (SAECG). Late potentials were investigated as a risk factor by nine studies, which predominantly 273 
reported non-significant results (Supplementary Table 2E). Meta-analyses confirmed no predictive 274 
value of ≥1 late potential criterion in definite ARVC patients (six studies, pooled HR 1.03 [95%CI 0.61-275 
1.72]), and borderline ARVC patients (three studies, pooled HR 1.4 [95%CI 0.86-2.3]; Figure 4). 276 
QRS-fragmentation · is defined as additional deflections/notching at the beginning of QRS, on 277 
top of the R-wave, or in the nadir of the S-wave in either ≥1 right precordial lead or in >1 other leads. 278 
QRS-fragmentation was reported as a risk factor in three studies, which all reported significant results: 279 
HR 8.54 (95%CI 3.65-15.42) and OR 11.64 (95%CI 5.1-16.41) in definite ARVC patients, and HR 280 
1.76 (95%CI 1.01-3.06) in borderline ARVC patients. Meta-analysis was not feasible due to 281 
heterogeneity in patient domain and utilized statistics. 282 
Other · potential ECG-derived predictor variables were investigated for which the results can 283 
be found in Supplementary Table 2E.  284 
 285 
Arrhythmias 286 
Premature Ventricular Complexes (PVCs) · on continuous ECG monitoring were analyzed as 287 
a risk factor by 11 studies. Variability in definitions (e.g. total 24-hour PVC count vs. various cut-offs) 288 
limits comparability of results. Three studies, two with definite ARVC patients and one with mutation 289 
carriers, found an increased arrhythmic risk in patients with >500 PVCs/24hrs, whereas results in 290 
borderline ARVC patients were non-significant (Supplementary Table 2F). Meta-analysis was solely 291 
feasible for two studies analyzing >1000 PVCs/24hrs in definite ARVC patients: pooled HR 0.86 292 
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(95%CI 0.45-1.64)(Figure 4). 293 
Non-sustained VT · is defined as ≥3 ventricular complexes at ≥100beats/minute, and was 294 
analyzed as a predictor of sustained ventricular events in 11 studies. A significant association was 295 
reported in 1/5 studies with definite ARVC patients, 1/3 studies with borderline ARVC patients, and 296 
2/3 studies in mutation carriers (Supplementary Table 2F). Meta-analysis was feasible for three 297 
studies with definite ARVC patients, yielding a significantly increased risk for patients who 298 
experienced non-sustained VT (pooled HR 1.43 [95%CI 1.10-2.15]; Figure 4). 299 
Sustained VT/VF · is defined as a documented ventricular arrhythmia at ≥100 beats/minute, 300 
lasting ≥30 seconds or with hemodynamic compromise requiring termination. Prior sustained VT/VF 301 
was analyzed as a risk factor for recurring sustained ventricular arrhythmias by 17 studies. The 302 
majority of studies reported an increased risk of recurring events in definite (n=8/13 studies) and 303 
borderline (n=3/4 studies) patients (Supplementary Table 2F). Meta-analysis was feasible for three 304 
studies with definite ARVC patients, resulting in a significantly higher risk for patients with a prior 305 
sustained VT/VF (pooled HR 2.05 [95%CI 1.08-3.88]; Figure 4). 306 
Other · reported risk factors are available in Supplementary Table 2F. 307 
 308 
Electrophysiology Study 309 
Inducibility of sustained ventricular arrhythmias · during EPS was evaluated as a predictor for 310 
spontaneous sustained ventricular arrhythmias by 15 studies. Despite the heterogeneity of stimulation 311 
protocols between studies, all (n=5/5) studies with borderline ARVC patients reported a significant 312 
association between inducibility and future arrhythmic events, whereas 9/10 studies with definite 313 
ARVC patients reported non-significant results (Supplementary Table 2G). The same trend was 314 
observed in meta-analysis of three studies with borderline ARVC patients (pooled HR 3.24 [95%CI 315 
1.95-5.39]) and two studies with definite ARVC patients (pooled HR 1.02 [95%CI 0.39-2.64]; Figure 316 
4). 317 
Other · variables derived from EPS include low-voltage zones, epicardial voltage mapping, 318 
sub-specification of inducible ventricular arrhythmias, and fragmented electrograms, for which results 319 
are presented in Supplementary Table 2G. 320 
 321 
Structural/Functional imaging 322 
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Reduced RV ejection fraction (RVEF) · was analyzed as a risk factor by 11 studies. While 323 
most (n=8/11) studies were directed towards increased arrhythmic risk with decreasing RVEF, 324 
statistical significance was only reached in 2/8 studies with definite ARVC patients, 0/2 studies with 325 
borderline ARVC patients, and 1/1 studies with mutation carriers (Supplementary Table 2H). Meta-326 
analysis was feasible for four studies with definite ARVC patients resulting in a borderline significant 327 
increased risk per 5% RVEF reduction, pooled HR of 1.89 (95%CI 0.90-3.99)(Figure 4). 328 
Reduced RV fractional area change (RVFAC) · was analyzed as a risk factor by five studies, 329 
most (n=3/5) of which reported a significantly increased arrhythmic risk with decreasing RVFAC: a 330 
significant association was observed in 1/3 studies with definite ARVC patients and 2/2 studies with 331 
borderline ARVC patients (Supplementary Table 2H). Meta-analysis was feasible for two studies with 332 
definite ARVC patients, resulting in a borderline significant increased risk per 5% RVFAC reduction, 333 
pooled HR 1.25 (95%CI 0.89-1.15)(Figure 4). 334 
RV wall motion abnormalities · by qualitative assessment was analyzed as a risk factor by 335 
four studies. All studies in definite (n=2) and borderline (n=1) ARVC patients reported non-significant 336 
results (Supplementary Table 2H), whereas one study with mutation carriers found a significant 337 
association with arrhythmic risk (OR 70.59 [3.91-1273.69]). Of note, quantitative wall motion 338 
assessment using echocardiography-derived strain was associated with arrhythmic events in patients 339 
with definite or borderline ARVC (OR 1.25 [95%CI 1.08-1.44] per % strain reduction; Supplementary 340 
Table 2H). Meta-analysis for either qualitative or quantitative RV wall motion assessment was not 341 
feasible due to heterogeneity in patient domain, variable definitions, and utilized statistics. 342 
Fulfillment of RV imaging criteria · as defined by the 2010 TFC was evaluated as a risk factor 343 
by ten studies. While studies in definite (n=5) and borderline (n=2) ARVC patients found no difference 344 
in arrhythmic risk, three studies with mutation carriers reported a higher arrhythmic risk for those 345 
fulfilling major imaging criteria (Supplementary Table 2H). Meta-analysis was feasible for four studies 346 
with definite ARVC patients, yielding non-significant results for fulfillment of any RV imaging criterion: 347 
pooled HR 1.09 (95%CI 0.65-1.84)(Figure 4). 348 
Reduced LV ejection fraction (LVEF) · was analyzed as a risk factor by 17 studies. The 349 
majority of studies in definite ARVC patients (n=9/10) and borderline ARVC patients (n=4/5) reported 350 
no effect on arrhythmic risk, whereas all two studies in mutation carriers reported a significant 351 
association between reduced LVEF and arrhythmic events (Supplementary Table 2H). Meta-analysis 352 
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in four studies with definite ARVC patients and two studies with borderline ARVC patients yielded 353 
non-significant results: pooled HR 1.16 (95%CI 0.87-1.54) and pooled HR 1.05 (95%CI 0.93-1.19), 354 
respectively, per 5% LVEF reduction (Figure 4). 355 
Other · imaging parameters are reported in Supplementary Table 2H. 356 
 357 
Sensitivity Analyses 358 
Of the 18 studies included in our meta-analysis, two used the original 1994 TFC as opposed 359 
to the modified 2010 TFC, which remain the current gold standard for ARVC diagnosis. Furthermore, 360 
four studies reported on primary prevention patients only, while others included patients with prior 361 
sustained events. To analyze the effect of these selection differences, all analyses were repeated by 362 
excluding studies that (1) used the 1994 TFC, and (2) included secondary prevention patients. As 363 
shown in Supplementary Table 3, pooled estimates remained similar for all risk factors, except for 364 
prior non-sustained VT (in both analyses), and male sex (in primary prevention studies) which lost 365 
their statistical significance. 366 
 367 
Discussion 368 
This manuscript aimed to systematically review predictors for ventricular arrhythmias in 369 
ARVC, highlight the quality of evidence as well as its shortcomings, and determine promising risk 370 
factors per patient subgroup (i.e. definite ARVC patients, borderline ARVC patients, and mutation 371 
carriers). We have summarized our key findings and clinical recommendations in Figure 5.  372 
 373 
Quality of Evidence 374 
Although a relatively large number of studies investigated potential risk factors for ventricular 375 
arrhythmias in ARVC, the majority (n=43/45) of studies were conducted in observational cohorts 376 
(n=14 prospective, n=17 retrospective, n=12 pro- and retrospective), which are inherently (but not 377 
necessarily) limited in quality of evidence. Important sources of bias were differences in follow-up 378 
time, selective loss to follow-up, and selection towards patients presenting alive (left truncation bias). 379 
Correcting for these factors is essential for accuracy and generalizability of results, and fortunately 380 
many authors performed at least some level of adjustment. However, as ARVC studies are typically 381 
small, the potential for adequate adjustment is often limited by insufficient statistical power. This 382 
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resulted in a variable risk of bias which is partly reflected by the inconsistency of reported results.   383 
To compensate for the relatively small study populations, we attempted to pool results into a 384 
quantitative meta-analysis to obtain more evidence for the most commonly reported risk factors. Of 385 
note, pooling of results is only appropriate in the setting of uniform definitions. Since individual studies 386 
used variable predictor definitions and risk estimates, the number of studies satisfying this 387 
prerequisite was unfortunately limited.  388 
Given both the limitations in individual study quality (as highlighted by the variable risk of bias) 389 
and our inability to pool all available results, we deem the overall quality of available evidence to be 390 
moderate. While this opens the path for future studies to specifically address these shortcomings, this 391 
should be taken into account when interpreting the main findings of this manuscript. 392 
 393 
Main Findings 394 
Overall Risk of Ventricular Arrhythmias in ARVC 395 
We found that the proportion of patients experiencing sustained ventricular arrhythmias in 396 
ARVC was relatively high (up to 30.1%/year). It is important to note that the highest of these 397 
proportions were observed in cohorts with a high a priori risk (e.g. severely affected definite ARVC 398 
patients). Indeed, the proportion of arrhythmic events was strongly associated with overt disease 399 
expression and ranged from 10.6%/year in definite patients, to 10.0%/year in borderline patients, to 400 
3.7%/year in mutation carriers. 401 
 402 
Risk Factors for Ventricular Arrhythmias are Domain-Dependent 403 
 The patient domain (i.e. study population) is a fundamental principle of clinical research and 404 
dictates to whom the reported results apply. Given the variability in patient domain across studies, we 405 
classified the included studies in three pre-specified domains: studies with definite ARVC patients 406 
only, studies with at least borderline ARVC patients (among whom a proportion had definite ARVC), 407 
and studies with ARVC-associated mutation carriers (among whom a [smaller] proportion had definite 408 
ARVC). Our separate analyses in these domains highlighted a pattern in the predictive value of risk 409 
factors based on the population. This is easily understandable in the context of their acquisition: most 410 
risk factors are related to disease expression, and therefore they typically overlap with diagnostic 411 
criteria. This is also in line with a recent publication suggesting that phenotypic expression is a 412 
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prerequisite for arrhythmic events in desmosomal mutation carriers.9 As such, these risk factors 413 
correlate well with arrhythmic events when studied in a cohort of mutation carriers, but their potential 414 
to risk stratify patients with an established ARVC diagnosis is limited since the risk factor is present in 415 
most subjects. For example, T-wave inversions in V1-3 remained non-significant in definite patients, 416 
while conflicting results were obtained in borderline patients, and a strong association was reported 417 
among mutation carriers. We believe that the variability in patient domains explains at least some of 418 
the conflicting results that were pointed out by previous reviews and guidelines.4,10  419 
 420 
Main Risk Factors for Ventricular Arrhythmias in ARVC 421 
Figure 6 provides an overview of risk factors and their predictive potential specified by patient 422 
domain. In definite ARVC patients, consistently predictive risk factors included unexplained syncope, 423 
TWI extent, RV dysfunction, and previously registered (non-)sustained VT/VF. In addition, males were 424 
found to be at higher risk of ventricular arrhythmia than females. This is in line with a recently 425 
published study that reported an association between elevated testosterone levels and arrhythmic 426 
events in ARVC.11 427 
In borderline ARVC patients, additional risk factors were found to be significant. In addition to 428 
the risk factors observed in definite ARVC patients, substantial evidence indicated a predictive effect 429 
of strenuous exercise and inducibility at EPS. 430 
In ARVC-associated mutation carriers (including asymptomatic patients), the list of predictors 431 
expanded even further, and also included the presence of symptoms (palpitations, pre-syncope 432 
and/or syncope), harboring multiple mutations, LV dysfunction, and ventricular ectopy.  433 
 434 
Limitations and Future Directives 435 
Given the nature of our study as a systematic review, our analyses are limited by the reported 436 
data in the original reports. Since almost all studies used a composite arrhythmic endpoint of 437 
sustained ventricular arrhythmias and/or ICD interventions, their outcomes may have included non-438 
life-threatening arrhythmias. Future studies should specifically confirm whether the predictors 439 
highlighted in this review also remain significant for truly life-threatening (cycle length <240 440 
milliseconds or VF) arrhythmias. The reported HRs from all 45 studies were cause-specific. As such, 441 
the results cannot directly be translated to event rates. Nonetheless, our study results remain 442 
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meaningful for characterizing risk factors associated with arrhythmic events. Despite our efforts to 443 
analyze the three pre-defined domains separately, some level of heterogeneity in study population 444 
remains as some studies employed specific inclusion criteria, e.g. ICD carriers or secondary 445 
prevention populations. We accounted for this by fully disclosing the study populations, refraining from 446 
using these studies in our pooled analyses, and performing sensitivity analyses. Although meta-447 
analysis potentially increases the power of pooled crude associations, it does not eliminate potential 448 
confounding, which is reflected by the severe heterogeneity of some pooled estimates in our study. 449 
Some of the included references only report adjusted values when significant in univariable analysis, 450 
which results in publication bias that cannot be corrected in our analyses. In addition, the design of 451 
this study as a systematic review limited our ability to analyze arrhythmic risk based on number of risk 452 
factors. Quantification of cumulative arrhythmic risk based on number of risk factors may help guide 453 
risk/benefit considerations of ICD placement in the individual patient. These limitations can only be 454 
overcome by developing a comprehensive arrhythmia prediction model that incorporates multiple risk 455 
factors. Development of such a prediction model will require a multicenter collaborative effort to obtain 456 
survival data on a large group of ARVC patients, so that absolute risk estimations can be made based 457 
on individual patient characteristics. 458 
 459 
Conclusion 460 
This study aimed to systematically review current evidence on arrhythmic risk stratification in 461 
ARVC. The average annual risk of ventricular arrhythmia ranged from 3.7% to 10.6%/year depending 462 
on the ARVC population. Since many predictors for ventricular arrhythmias overlap with diagnostic 463 
criteria, the potential to risk stratify patients with an established ARVC diagnosis is limited. 464 
Regardless, consistently predictive risk factors for ventricular arrhythmias are male sex, unexplained 465 
syncope, TWI beyond V3, RV dysfunction and previously registered (non-)sustained VT/VF. Since 466 
most evidence originates from observational cohort studies in small patient cohorts, one has to be 467 
critical of the quality of evidence. Future studies in collaborative international registries should 468 
investigate the incremental value of multiple risk factors so that accurate risk predictions can be made 469 
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Figure 2. Study Characteristics of 45 Included Studies†.520 
 521 
For full references see supplementary material. Follow-up is in average±SD or median[IQR]. Abbreviations: ATP=anti-tachycardia pacing; CC=case-control study; CS=cross-sectional study; 522 
P=primary prevention; PC=prospective cohort; PV=predictive value; RC=retrospective cohort; RFA=radiofrequency ablation; S=secondary prevention; others: see text. 523 
† There was potential overlap in 41 studies, in case of overlap, only results from the largest population were incorporated.524 
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Figure 4.  528 
 529 
Summary of Meta-Analysis Results. Pooled HR with 95%CI are plotted. Filled circles correspond to 530 
studies with definite ARVC patients, empty circles to studies with (at least) borderline ARVC subjects. 531 
Circles size is scaled to the number of events. I2=Chi-square test of heterogeneity(%). Abbreviations: 532 




Figure 5. Key Messages and Clinical Recommendations. 535 
 536 




Figure 6.  539 
 540 
 541 
Predictors for Sustained VA Are Population-Dependent. Predictors are plotted by patient domain. The 542 
dark region (small circle) applies to definite ARVC patients; dark region plus lighter region 543 
(intermediate circle) applies to at least borderline ARVC patients; the full ellipse applies to mutation 544 
carriers. Abbreviations: see text. 545 
